Therapy News and Research

RSS

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

How do green spaces in urban areas impact anxiety and depression outcomes?

Researchers reassessed the impact of green spaces in countering some of this mental stress in urban areas.

5 Jun 2023

Women taking oral estrogen therapy more likely to develop high blood pressure

Women ages 45 years and older taking estrogen hormone therapy in pill form were more likely to develop high blood pressure than those using transdermal (topical, applied to the skin) or vaginal formulations, according to new research published today in Hypertension, a peer-reviewed American Heart Association journal.

5 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

Gene alterations in biliary tract cancer offer potential targets for effective precision therapies

Gene alterations in biliary tract cancer offer potential targets for current or future precision therapies. This is demonstrated by a highly acclaimed study conducted by Karl Landsteiner University of Health Sciences in collaboration with the Medical University of Vienna.

5 Jun 2023

Lindus Health secures funding to accelerate the use of technology for revolutionizing clinical trials

Ground-breaking trials run by London-based start-up Lindus Health are kicking off to find innovative treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.

5 Jun 2023

Research opens door to new, more efficient drug combinations for acute myeloid leukemia

Acute myeloid leukemia (AML) is a very aggressive disease in which cells proliferate abnormally, invading the bone marrow and interfering with normal blood cell production. It is the most common acute leukemia in adults with the worst prognosis.

5 Jun 2023

Study suggests possible new treatment option for people with slow-growing but deadly brain tumor

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening.

4 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer

Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease.

4 Jun 2023

Combination therapy successfully treats Pasteurella multocida-related invasive infections

Announcing a new article publication for Zoonoses journal. Pasteurella multocida, a Gram-negative, penicillin-sensitive coccobacillus that is frequently a member of the normal respiratory microbiota of different animals, remains a clinically important pathogen with the ability to cause severe disease. Few case reports have involved P. multocida infections without animal bites.

4 Jun 2023

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

4 Jun 2023

Groundbreaking study maps molecular architecture of the visual system's integral components

A groundbreaking study has taken a significant step towards understanding the complexities of the human eye.

4 Jun 2023

Can exercise ease anxiety? Study investigates the potentials and pitfalls of fitness as therapy

A comprehensive analysis of 25 clinical trials on exercise interventions reveals inconclusive and negative results regarding its efficacy in treating anxiety disorders. Methodological limitations indicate exercise is not currently an effective intervention for anxiety.

4 Jun 2023

Researchers characterize a unique molecular mechanism of early stages of programmed cell death

Researchers have for the first time characterized a unique molecular mechanism of the early stages of programmed cell death or apoptosis, a process which plays a crucial role in prevention of cancer.

2 Jun 2023

New collaboration wins award to investigate non-invasive treatment of uterine fibroids

A collaboration among Dr. Frank Greenway of Pennington Biomedical Research Center, Dr. Beverly Ogden of Woman's Hospital in partnership with LSU, and the University of Louisiana at Lafayette, was named as one of three award recipients at the Baton Rouge Health-Tech Catalyst Pitch Night.

2 Jun 2023

ACNAP 2023 highlights the artistic and scientific dimensions of cardiovascular care

Hear from patients, nurses and allied health professionals about hot topics in cardiovascular disease at ACNAP 2023, a scientific congress of the European Society of Cardiology.

2 Jun 2023

Study of immunotherapy for brain cancer metastases shows promising results

In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving longer than two years.

2 Jun 2023

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.

2 Jun 2023

University of Louisville researchers receive $5.8 million to prevent immune system dysregulation

Researchers at the University of Louisville have received $5.8 million in two grants from the National Institutes of Health to expand their work to better understand and prevent immune system dysregulation responsible for acute respiratory distress, the condition responsible for serious illness and death in some COVID-19 patients.

2 Jun 2023

Therapy News and Research

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

How do green spaces in urban areas impact anxiety and depression outcomes?

Women taking oral estrogen therapy more likely to develop high blood pressure

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Gene alterations in biliary tract cancer offer potential targets for effective precision therapies

Lindus Health secures funding to accelerate the use of technology for revolutionizing clinical trials

Research opens door to new, more efficient drug combinations for acute myeloid leukemia

Study suggests possible new treatment option for people with slow-growing but deadly brain tumor

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer

Combination therapy successfully treats Pasteurella multocida-related invasive infections

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Groundbreaking study maps molecular architecture of the visual system's integral components

Can exercise ease anxiety? Study investigates the potentials and pitfalls of fitness as therapy

Researchers characterize a unique molecular mechanism of early stages of programmed cell death

New collaboration wins award to investigate non-invasive treatment of uterine fibroids

ACNAP 2023 highlights the artistic and scientific dimensions of cardiovascular care

Study of immunotherapy for brain cancer metastases shows promising results

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

University of Louisville researchers receive $5.8 million to prevent immune system dysregulation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News